Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 15/20 | 0.46 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | TXK | P42681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832186 | 0.93 | NTRK1 (0.47) | NTRK1JAK3BTKKDRITK | |
| SCHEMBL2066653 | 0.83 | NTRK1 (0.42) | NTRK1JAK3BTKKDRITK | |
| SCHEMBL3825428 | 0.80 | NTRK1 (0.49) | NTRK1JAK3BTKKDRITK | |
| SCHEMBL3827871 | 0.77 | NTRK1 (0.38) | NTRK1JAK3BTKKDRITK | |
| SCHEMBL3827914 | 0.74 | NTRK1 (0.51) | NTRK1JAK3BTKKDRITK | |
| SCHEMBL3832197 | 0.74 | NTRK1 (0.45) | NTRK1JAK3BTKKDRTXK | |
| SCHEMBL2066201 | 0.72 | NTRK1 (0.43) | NTRK1JAK3BTKKDRITK | |
| SCHEMBL2066843 | 0.72 | NTRK1 (0.43) | NTRK1JAK3BTKKDRITK | |
| SCHEMBL2066204 | 0.72 | NTRK1 (0.43) | NTRK1JAK3BTKKDRITK | |
| SCHEMBL2065674 | 0.69 | NTRK1 (0.54) | NTRK1JAK3BTKKDRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099794-A2 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008079873-A2 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-03 | — | — | WO | disclosed |